Indeed, treating HCC cells and organoids with a combination of rTHBS2 and 5‐FU resulted in a marked decrease in CD133 expression, as evidenced by an in vitro 3D matrix gel culture setup (Figure S4D, Supporting Information) and an in vivo intrahepatic HCC animal model. The gene discussed is PROM1; the disease is hepatocellular carcinoma.